达格列净对射血分数降低心衰患者新发2型糖尿病的影响:DAPA-HF探索性分析
本探索性分析纳入DAPA-HF试验中2,605例无糖尿病史且基线HbA1c<6.5%的射血分数降低心衰患者,随机接受达格列净10 mg每日一次或安慰剂。中位随访18个月,达格列净组新发糖尿病发生率为4.9%,安慰剂组为7.1%,达格列净使糖尿病发生率降低32%(HR 0.68,95%CI 0.50-0.94;P=0.019)。
要点
- 在无糖尿病的心衰患者中,达格列净使新发2型糖尿病风险降低32%。
- 发生糖尿病者基线多处于糖尿病前期(HbA1c 5.7-6.4%)。
- 该获益为探索性结果,需更长期及非心衰人群试验确认。
核心结论
- 在HFrEF且无糖尿病的患者中,达格列净治疗降低了新发糖尿病发生率。
研究设计与样本
- DAPA-HF试验的探索性分析,纳入2,605例无糖尿病史且基线HbA1c<6.5%的HFrEF患者,随机接受达格列净10 mg每日一次或安慰剂。
主要发现
- 中位随访18个月,安慰剂组1,307例中93例(7.1%)发生糖尿病,达格列净组1,298例中64例(4.9%)发生糖尿病。
- 达格列净使糖尿病发生率降低32%(HR 0.68,95%CI 0.50-0.94;P=0.019)。
- 基线平均HbA1c为5.8%,8个月时安慰剂校正的达格列净组变化为-0.04%。
- 发生2型糖尿病者中超过95%基线处于糖尿病前期(HbA1c 5.7-6.4%)。
- DAPA-HF中发生糖尿病者后续死亡率高于未发生者。
临床怎么用
- 对HFrEF合并糖尿病前期患者,达格列净在改善心衰结局的同时可能减少新发糖尿病。
局限性
- 为探索性分析,新发糖尿病通过方案规定的周期性HbA1c检测监测。
- 该潜在获益需更长期试验及非心衰人群试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial. RESEARCH DESIGN AND METHODS: The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg daily or placebo. In this exploratory analysis, surveillance for new-onset diabetes was accomplished through periodic HbA1c testing as part of the study protocol and comparison between the treatment groups assessed through a Cox proportional hazards model. RESULTS: At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a placebo-adjusted change in the dapagliflozin group of -0.04%. Over a median follow-up of 18 months, diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (hazard ratio 0.68, 95% CI 0.50-0.94; P = 0.019). More than 95% of the participants who developed T2D had prediabetes at baseline (HbA1c 5.7-6.4%). Participants who developed diabetes in DAPA-HF had a higher subsequent mortality than those who did not. CONCLUSIONS: In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.
引用
- Inzucchi SE, Docherty KF, Køber L, et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2020. PMID: 33355302. doi:10.2337/dc20-1675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。